Custer

Researchers are investigating the effects of sacituzumab govitecan (SG; Trodelvy®; GS-0132; IMMU 132) compared to standard treatments in people with previously treated extensive stage small cell lung cancer (ES-SCLC). The main goal is to compare how SG versus standard care impacts overall survival up to 4.5 years after treatment. This phase 3, global, multicenter, randomized, open-label study focuses on participants who have already received prior platinum-containing chemotherapy. Participants are randomly assigned to receive either sacituzumab govitecan or one of the standard care drugs, including topotecan, amrubicin (in Japan only), or lurbinectedin (where approved). All drugs are given by intravenous infusion. The study includes a treatment period where these medications are administered according to the protocol, with doses and schedules managed by the study teams. During the study, participants will be monitored regularly for overall survival and other health outcomes. Assessments will include imaging scans like CT or MRI to measure disease status, along with clinical evaluations and symptom monitoring. The study tracks safety and treatment effects over time, aiming for a follow-up of up to 4.5 years. Participants will have their condition reviewed throughout to evaluate how the treatments impact their survival and disease progression.